Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. Jun 24, 2022; 13(6): 520-528
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.520
Table 1 Comparisons of patients’ characteristics according to the presence of lymph node metastasis of pancreatic neuroendocrine neoplasm
VariablesTotal (n = 82)N- (n = 72)N+ (n = 10)P value
Age, median (range)59 (18-81)58 (18-80)63 (18-81)0.65
Gender (male/female)41/4135/376/40.50
Tumor size, median, mm (range)12 (5-90)12 (5-90)37 (12-75)0.0001
Tumor number (single/multiple)68/1459/139/10.50
Tumor location (Ph/Pb/Pt/Ph and Pt)32/23/25/223/22/25/29/1/0/00.15
Symptoms (yes/no)35/4731/414/60.85
CT Enhancement (hyper/hypo)72/1064/88/20.17
Type of PNEN, n (%)NS
Insulinoma26 (32)260
Gastrinoma2 (2.5)11
Glucagonoma2 (2.5)20
VIPoma1 (1)10
Non functional51 (62)429
WHO classification 2017, n (%)0.0009
NET G170 (85)664 (6%)
NET G29 (11)54 (44%)
NET G3/NEC3 (4)12 (67%)
Surgical procedure, n (%)NS
Pancreatoduodenectomy (PD)23 (28)158
Distal pancreatectomy (DP)38 (46)371
PD + DP2 (2.5)20
Enucleation/partial pancreatectomy19 (23)181